Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Blog

  • Home
  •  
  • Blog



  • Most Read
  • Latest Comments
  • Blog
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Blog
    • Satire

    Australia to close borders to Omicron Persei 8
    Public
  • Blog
    • Opinion

    The New Criterion: will the listed sanitiser stocks clean up – or clean out – investors?
    Public
  • Blog
    • Opinion

    Is this the most hated company on the ASX?
    Public
  • Blog
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • AML3D announces stronger FY26, with positive EBITDA reported in the second half
    AML3D announces stronger FY26, with positive EBITDA reported in the second half
    • News

  • Refurbished tech gives Harris Technology a second life
    Refurbished tech gives Harris Technology a second life
    • News

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    • News

  • We wade through this radiopharmaceutical company’s news so you don’t have to
    • News

    We wade through this radiopharmaceutical company’s news so you don’t have to

    Seeing ‘Cu-64 SAR-bisPSMA’ in the title of an ASX announcement is enough to make many keep scrolling. However, clued in investors who read on and plug ‘radiopharmaceuticals’ into their search bar will uncover the massive market value of the space and its transformative potential. Clinical stage radiopharmaceutical company Clarity Pharmaceuticals (ASX: CU6) is an oncologyRead More
    Public
  • PainChek expands across New Zealand with pain tech deployed to 24 aged care facilities
    • News

    PainChek expands across New Zealand with pain tech deployed to 24 aged care facilities

    Confident in their technology that can accurately assess a patient’s pain simply from a short video of their face, medtech company PainChek (ASX: PCK) has successfully converted a 6-month trial with one of New Zealand’s largest aged care operators into a full revenue-generating contract. The contract comes after Summerset Holdings (ASX: SNZ) trialled PainChek’s smartphone

    Read More
    Public
  • German Ice Hockey Federation to trial HITIQ’s concussion tech mouthguards
    • News

    German Ice Hockey Federation to trial HITIQ’s concussion tech mouthguards

    With the AFL season having just kicked off, it didn’t take long for attention to be drawn to the league’s concussion protocols but having already partnered with the AFL, concussion tech company HITIQ (ASX: HIQ) has continued its international expansion having been engaged by the German Ice Hockey Federation. The long-term impact of concussion continues

    Read More
    Public
  • Conversational AI & the Metaverse: The Future of Digital Interaction
    • Opinion

    Conversational AI & the Metaverse: The Future of Digital Interaction

    The age of the metaverse is upon us; touted by Big Tech experts as the coming of the next internet and predicted to deliver a transcendent, immersive and 3D cyber experience. It presents an opportunity to redefine interactions by removing limitations and allowing conversations to take place through the humanisation of artificial objects. In this

    Read More
    Public
  • Predictive test for diabetic kidney disease receives new patent
    • News

    Predictive test for diabetic kidney disease receives new patent

    12% of global health expenditure is spent on diabetes. That equates to approximately USD $673 billion. Scarily, 1 in 2 adults with diabetes is undiagnosed.  Diabetic kidney disease (DKD) is directly caused by diabetes, and the damage the disease does to the kidneys. It is estimated that 1 in 3 diabetics will go on to

    Read More
    Public
  • Cettire founder cashes out $47m as boom stock comes back down to earth
    • News

    Cettire founder cashes out $47m as boom stock comes back down to earth

    If shareholder confidence is a sign of things to come, rocky waters may be ahead for luxury goods retailer Cettire (ASX: CTT) after its Founder and CEO cashed out $47.25 million of his shares with a pretty good idea of how their financial results for the year are going to look.  Keen investors have been

    Read More
    Public
  • «
  • ‹
  • 395
  • 396
  • 397
  • 398
  • 399
  • ›
  • »

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.